{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:41:05Z","timestamp":1771476065603,"version":"3.50.1"},"reference-count":134,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.critrevonc.2016.08.011","type":"journal-article","created":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T22:50:48Z","timestamp":1473288648000},"page":"20-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?"],"prefix":"10.1016","volume":"107","author":[{"given":"Giuseppe","family":"Bronte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"Incorvaia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Passiglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Galvano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Rolfo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Fanale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"List\u00ec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7295-0230","authenticated-orcid":false,"given":"Clara","family":"Natoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana","family":"Bazan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4370-2008","authenticated-orcid":false,"given":"Antonio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.critrevonc.2016.08.011_bib0005","doi-asserted-by":"publisher","first-page":"5876","DOI":"10.1158\/1078-0432.CCR-07-0883","article-title":"Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors","volume":"13","author":"Ali","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2016.08.011_bib0010","article-title":"Single-Agent pembrolizumab for patients with malignant pleural mesothelioma (MPM)","author":"Alley","year":"2015","journal-title":"Paper Presented At: International Association for the Study of Lung Cancer, 16th World Conference on Lung Cancer"},{"issue":"40","key":"10.1016\/j.critrevonc.2016.08.011_bib0015","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1038\/sj.onc.1208744","article-title":"Human and mouse mesotheliomas exhibit elevated AKT\/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth","volume":"24","author":"Altomare","year":"2005","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.critrevonc.2016.08.011_bib0020","doi-asserted-by":"publisher","first-page":"e18828","DOI":"10.1371\/journal.pone.0018828","article-title":"Losses of both products of the Cdkn2a\/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis","volume":"6","author":"Altomare","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2016.08.011_bib0025","unstructured":"Nintedanib (BIBF 1120) in Mesothelioma. ClinicalTrials.gov Identifier: NCT01907100. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01907100."},{"key":"10.1016\/j.critrevonc.2016.08.011_bib0030","unstructured":"A Study of LY3023414 in Participants With Advanced Cancer. http:\/\/clinicaltrials.gov\/show\/NCT01655225."},{"key":"10.1016\/j.critrevonc.2016.08.011_bib0035","unstructured":"Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma (COMMAND). ClinicalTrials.gov Identifier: NCT01870609. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01870609."},{"key":"10.1016\/j.critrevonc.2016.08.011_bib0040","unstructured":"Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma (MESO-02). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01590160."},{"key":"10.1016\/j.critrevonc.2016.08.011_bib0045","unstructured":"Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (TRAP). ClinicalTrials.gov Identifier: NCT02029690. https:\/\/clinicaltrials.nlm.nih.gov\/ct2\/show\/NCT02029690."},{"key":"10.1016\/j.critrevonc.2016.08.011_bib0050","unstructured":"A Study of Cetuximab Combined With Cisplatin or Carboplatin\/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma. (MesoMab) ClinicalTrials.gov Identifier: NCT00996567. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00996567."},{"issue":"5","key":"10.1016\/j.critrevonc.2016.08.011_bib0055","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0046-8177(98)90066-1","article-title":"Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders","volume":"29","author":"Arber","year":"1998","journal-title":"Hum. Pathol."},{"issue":"Suppl. 5","key":"10.1016\/j.critrevonc.2016.08.011_bib0060","doi-asserted-by":"publisher","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Baas","year":"2015","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2016.08.011_bib0065","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1136\/thx.2003.008912","article-title":"Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma","volume":"59","author":"Baldi","year":"2004","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.critrevonc.2016.08.011_bib0070","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S1470-2045(13)70257-2","article-title":"Asbestos is not just asbestos: an unrecognised health hazard","volume":"14","author":"Baumann","year":"2013","journal-title":"Lancet Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2016.08.011_bib0075","doi-asserted-by":"publisher","first-page":"16848","DOI":"10.18632\/oncotarget.4253","article-title":"Reactive oxygen species a double-edged sword for mesothelioma","volume":"6","author":"Benedetti","year":"2015","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.critrevonc.2016.08.011_bib0080","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1136\/thx.2006.069872","article-title":"Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed","volume":"62","author":"Bertino","year":"2007","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.critrevonc.2016.08.011_bib0085","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.critrevonc.2016.08.011_bib0090","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.critrevonc.2013.08.003","article-title":"Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects","volume":"89","author":"Bronte","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.08.011_bib0095","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1517\/14712598.2015.963052","article-title":"Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario","volume":"15","author":"Bronte","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.08.011_bib0100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/14712598.2015.1075000","article-title":"Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?","volume":"16","author":"Bronte","year":"2016","journal-title":"Expert Opin. Biol. Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2016.08.011_bib0105","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S1470-2045(13)70125-6","article-title":"Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study","volume":"14","author":"Buikhuisen","year":"2013","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2016.08.011_bib0110","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study","volume":"3","author":"Calabr\u00f2","year":"2015","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2016.08.011_bib0115","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc3459","article-title":"BAP1 and cancer","volume":"13","author":"Carbone","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2016.08.011_bib0120","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/ijc.11710","article-title":"Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention","volume":"109","author":"Catalano","year":"2004","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2016.08.011_bib0125","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.cancergen.2015.07.004","article-title":"An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation","volume":"208","author":"Cheung","year":"2015","journal-title":"Cancer Genet."},{"issue":"2","key":"10.1016\/j.critrevonc.2016.08.011_bib0130","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/ijc.21271","article-title":"Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma","volume":"118","author":"Cortese","year":"2006","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2016.08.011_bib0135","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1200\/JCO.2005.09.112","article-title":"Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention","volume":"23","author":"Dannenberg","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2016.08.011_bib0140","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/bjc.1990.207","article-title":"Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R) Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody","volume":"61","author":"Dazzi","year":"1990","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2016.08.011_bib0145","first-page":"361","article-title":"Mutation analysis of the BRAF codon 599 in malignant pleural mesothelioma by enriched PCR-RFLP","volume":"11","author":"Dote","year":"2004","journal-title":"Oncol. Rep."},{"issue":"6","key":"10.1016\/j.critrevonc.2016.08.011_bib0150","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.hoc.2005.09.008","article-title":"Antiangiogenic therapies for mesothelioma","volume":"19","author":"Dowell","year":"2005","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"10","key":"10.1016\/j.critrevonc.2016.08.011_bib0155","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1097\/JTO.0b013e3181ec18db","article-title":"A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307","volume":"5","author":"Dubey","year":"2010","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2016.08.011_bib0160","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/JTO.0b013e318248242c","article-title":"Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report","volume":"7","author":"Dudek","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2016.08.011_bib0165","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1054\/bjoc.2001.1997","article-title":"Angiogenesis is an independent prognostic factor in malignant mesothelioma","volume":"85","author":"Edwards","year":"2001","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2016.08.011_bib0170","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.lungcan.2006.08.012","article-title":"EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma","volume":"54","author":"Edwards","year":"2006","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2016.08.011_bib0175","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/sj.onc.1210744","article-title":"BCL-2 family regulation by the 20S proteasome inhibitor bortezomib","volume":"27","author":"Fennell","year":"2008","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.critrevonc.2016.08.011_bib0180","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1097\/JTO.0b013e318260dfb9","article-title":"Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma","volume":"7","author":"Fennell","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2016.08.011_bib0185","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000087376","article-title":"Serum PDGF-AB in pleural mesothelioma","volume":"26","author":"Filiberti","year":"2005","journal-title":"Tumour Biol."},{"issue":"4","key":"10.1016\/j.critrevonc.2016.08.011_bib0190","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.aogh.2014.09.016","article-title":"The global spread of asbestos","volume":"80","author":"Frank","year":"2014","journal-title":"Ann. Glob. Health."},{"issue":"11","key":"10.1016\/j.critrevonc.2016.08.011_bib0195","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/sj.cgt.7700241","article-title":"Gene therapy of established mesothelioma xenografts with recombinant p16INK4a adenovirus","volume":"7","author":"Frizelle","year":"2000","journal-title":"Cancer Gene Ther."},{"issue":"41","key":"10.1016\/j.critrevonc.2016.08.011_bib0200","doi-asserted-by":"publisher","first-page":"5511","DOI":"10.1038\/onc.2008.246","article-title":"Drug discovery approaches targeting the PI3K\/Akt pathway in cancer","volume":"27","author":"Garcia-Echeverria","year":"2008","journal-title":"Oncogene"},{"issue":"17","key":"10.1016\/j.critrevonc.2016.08.011_bib0205","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.08.011_bib0210","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2147\/TCRM.S1603","article-title":"Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma","volume":"4","author":"Goudar","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"issue":"6","key":"10.1016\/j.critrevonc.2016.08.011_bib0215","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2016.08.011_bib0220","first-page":"5","article-title":"CTLA-4 blockade in tumor models: an overview of preclinical and translational research","volume":"13","author":"Grosso","year":"2013","journal-title":"Cancer Immun."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.08.011_bib0225","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejca.2007.08.028","article-title":"Mesothelin targeted cancer immunotherapy","volume":"44","author":"Hassan","year":"2008","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2016.08.011_bib0230","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.lungcan.2009.07.016","article-title":"Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy","volume":"68","author":"Hassan","year":"2010","journal-title":"Lung Cancer"},{"issue":"208","key":"10.1016\/j.critrevonc.2016.08.011_bib0235","doi-asserted-by":"publisher","first-page":"208ra147","DOI":"10.1126\/scitranslmed.3006941","article-title":"Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression","volume":"5","author":"Hassan","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"23","key":"10.1016\/j.critrevonc.2016.08.011_bib0240","doi-asserted-by":"publisher","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma","volume":"20","author":"Hassan","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"21","key":"10.1016\/j.critrevonc.2016.08.011_bib0245","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1002\/cncr.28875","volume":"120","author":"Hassan","year":"2014","journal-title":"Cancer"},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2016.08.011_bib0250","first-page":"7532","article-title":"Antimesothelin vaccine CRS-207 plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM)","volume":"32","author":"Hassan","year":"2014","journal-title":"ASCO Meet. Abstr."},{"issue":"6","key":"10.1016\/j.critrevonc.2016.08.011_bib0255","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1074\/jbc.M209200200","article-title":"Absence of p21CIP rescues myogenic progenitor cell proliferative and regenerative capacity in Foxk1 null mice","volume":"278","author":"Hawke","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.critrevonc.2016.08.011_bib0260","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1378\/chest.113.3.723","article-title":"Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B","volume":"113","author":"Herndon","year":"1998","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.critrevonc.2016.08.011_bib0265","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/bjc.2015.124","article-title":"Anti-programmed cell death protein-1\/ligand-1 therapy in different cancers","volume":"112","author":"Homet Moreno","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2016.08.011_bib0270","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.05.020","article-title":"The genetic landscape of malignant pleural mesothelioma: results from massively parallel sequencing","author":"Hylebos","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"16","key":"10.1016\/j.critrevonc.2016.08.011_bib0275","doi-asserted-by":"crossref","first-page":"21259","DOI":"10.18632\/oncotarget.7267","article-title":"Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma","volume":"7","author":"Incorvaia","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.critrevonc.2016.08.011_bib0280","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/cncr.23617","article-title":"Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma","volume":"113","author":"Jackman","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2016.08.011_bib0285","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1158\/0008-5472.CAN-04-4567","article-title":"Functional analysis of c-Met\/hepatocyte growth factor pathway in malignant pleural mesothelioma","volume":"66","author":"Jagadeeswaran","year":"2006","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2016.08.011_bib0290","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.lungcan.2011.11.014","article-title":"Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107)","volume":"76","author":"Jahan","year":"2012","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2016.08.011_bib0295","doi-asserted-by":"publisher","first-page":"6232","DOI":"10.1093\/nar\/gku274","article-title":"The forkhead transcription factor FOXK2 acts as a chromatin targeting factor for the BAP1-containing histone deubiquitinase complex","volume":"42","author":"Ji","year":"2014","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2016.08.011_bib0300","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S0092-8674(00)80452-3","article-title":"Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF","volume":"91","author":"Kamijo","year":"1997","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.critrevonc.2016.08.011_bib0305","doi-asserted-by":"publisher","first-page":"e105919","DOI":"10.1371\/journal.pone.0105919","article-title":"MET and PI3 K\/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma","volume":"9","author":"Kanteti","year":"2014","journal-title":"PLoS One"},{"issue":"suppl. 4","key":"10.1016\/j.critrevonc.2016.08.011_bib0310","doi-asserted-by":"publisher","first-page":"iv555","DOI":"10.1093\/annonc\/mdu358.32","article-title":"1601PVS-6063 (DEFACTINIB) targets mesothelioma cancer stem cells directly and through inhibition of tumor-associated macrophages and cytokine production","volume":"25","author":"Keegan","year":"2014","journal-title":"Ann. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2016.08.011_bib0315","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer","volume":"23","author":"Kelly","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2016.08.011_bib0320","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","article-title":"Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma","volume":"30","author":"Kindler","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"suppl., abstr 8502","key":"10.1016\/j.critrevonc.2016.08.011_bib0325","article-title":"Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): results from the global, double-blind, placebo-controlled DETERMINE study","volume":"34","author":"Kindler","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.08.011_bib0330","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2486\/indhealth.36.52","article-title":"Assessment of mutations of Ha- and Ki-ras oncogenes and the p53 suppressor gene in seven malignant mesothelioma patients exposed to asbestos?PCR-SSCP and sequencing analyses of paraffin-embedded primary tumors","volume":"36","author":"Kitamura","year":"1998","journal-title":"Ind. Health"},{"issue":"1","key":"10.1016\/j.critrevonc.2016.08.011_bib0335","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.lungcan.2005.07.010","article-title":"Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM)","volume":"51","author":"Klabatsa","year":"2006","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2016.08.011_bib0340","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/(SICI)1097-0215(19980413)76:2<240::AID-IJC12>3.0.CO;2-G","article-title":"Hepatocyte growth factor\/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c-met receptor","volume":"76","author":"Klominek","year":"1998","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2016.08.011_bib0345","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2016.08.011_bib0350","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1158\/1078-0432.CCR-11-2375","article-title":"New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment","volume":"18","author":"Ladanyi","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2016.08.011_bib0355","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1016\/j.lungcan.2005.03.017","article-title":"Implications of P16\/CDKN2A deletion in pleural mesotheliomas","volume":"49","author":"Ladanyi","year":"2005","journal-title":"Lung Cancer"},{"issue":"14","key":"10.1016\/j.critrevonc.2016.08.011_bib0360","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.2174\/1389450116666141205160924","article-title":"Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells","volume":"15","author":"Leon","year":"2014","journal-title":"Curr. Drug Targets"},{"issue":"4","key":"10.1016\/j.critrevonc.2016.08.011_bib0365","first-page":"516","article-title":"Inflammation in malignant mesothelioma \u2013 friend or foe?","volume":"1","author":"Linton","year":"2012","journal-title":"Ann. Cardiothorac. Surg."},{"issue":"17","key":"10.1016\/j.critrevonc.2016.08.011_bib0370","doi-asserted-by":"publisher","first-page":"6097","DOI":"10.1158\/1078-0432.CCR-05-1217","article-title":"Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways","volume":"11","author":"Lippman","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2016.08.011_bib0375","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/JTO.0000000000000436","article-title":"Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study","volume":"10","author":"Lo Iacono","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"46","key":"10.1016\/j.critrevonc.2016.08.011_bib0380","doi-asserted-by":"publisher","first-page":"35728","DOI":"10.1074\/jbc.M110.154005","article-title":"Cell cycle-dependent regulation of the forkhead transcription factor FOXK2 by CDK\u00b7cyclin complexes","volume":"285","author":"Marais","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.critrevonc.2016.08.011_bib0385","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1136\/oemed-2014-102297","article-title":"Malignant mesothelioma due to non-occupational asbestos exposure from the Italian national surveillance system (ReNaM): epidemiology and public health issues","volume":"72","author":"Marinaccio","year":"2015","journal-title":"Occup. Environ. Med."},{"key":"10.1016\/j.critrevonc.2016.08.011_bib0390","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0065-230X(04)91004-4","article-title":"Histone deacetylase inhibitors","volume":"91","author":"Marks","year":"2004","journal-title":"Adv. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.08.011_bib0395","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.lungcan.2005.04.010","article-title":"Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial","volume":"50","author":"Mathy","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2016.08.011_bib0400","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1146\/annurev-med-062913-051343","article-title":"The PI3K\/AKT pathway as a target for cancer treatment","volume":"67","author":"Mayer","year":"2016","journal-title":"Annu. Rev. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2016.08.011_bib0405","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.tcb.2009.02.006","article-title":"Merlin and the ERM proteins\u2013regulators of receptor distribution and signaling at the cell cortex","volume":"19","author":"McClatchey","year":"2009","journal-title":"Trends Cell Biol."},{"issue":"9","key":"10.1016\/j.critrevonc.2016.08.011_bib0410","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1183\/09031936.96.09091932","article-title":"The epidemiology of mesothelioma in historical context","volume":"9","author":"McDonald","year":"1996","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.critrevonc.2016.08.011_bib0415","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.envint.2014.10.016","article-title":"Impact of an asbestos cement factory on mesothelioma incidence: global assessment of effects of occupational, familial, and environmental exposure","volume":"74","author":"Mensi","year":"2015","journal-title":"Environ. Int."},{"issue":"3","key":"10.1016\/j.critrevonc.2016.08.011_bib0420","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/jso.1143","article-title":"Survival after conservative (palliative) management of pleural malignant mesothelioma","volume":"78","author":"Merritt","year":"2001","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.011_bib0425","article-title":"Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma","author":"Millward","year":"2003","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2016.08.011_bib0430","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.ajpath.2012.12.028","article-title":"New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas","volume":"182","author":"Mossman","year":"2013","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.08.011_bib0435","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1383-5718(00)00043-7","article-title":"Analysis of K-ras and p53 mutations in mesotheliomas from humans and rats exposed to asbestos","volume":"468","author":"Ni","year":"2000","journal-title":"Mutat. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.08.011_bib0440","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1158\/0008-5472.CAN-08-3355","article-title":"BRCA1-associated protein 1 interferes with BRCA1\/BARD1 RING heterodimer activity","volume":"69","author":"Nishikawa","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2016.08.011_bib0445","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.critrevonc.2016.05.004","article-title":"The third italian consensus conference for malignant pleural mesothelioma: state of the art and recommendations","volume":"104","author":"Novello","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2016.08.011_bib0450","first-page":"7036","article-title":"Final results of a phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM)","volume":"28","author":"Nowak","year":"2010","journal-title":"ASCO Meet. Abstr."},{"issue":"3","key":"10.1016\/j.critrevonc.2016.08.011_bib0455","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.lungcan.2013.05.006","article-title":"A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma","volume":"81","author":"Nowak","year":"2013","journal-title":"Lung Cancer"},{"issue":"13","key":"10.1016\/j.critrevonc.2016.08.011_bib0460","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1016\/j.ejca.2013.05.008","volume":"49","author":"O'Brien","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2016.08.011_bib0465","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/j.ejca.2005.04.019","article-title":"Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma","volume":"41","author":"O'Kane","year":"2005","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2016.08.011_bib0470","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.lungcan.2009.04.008","article-title":"COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines","volume":"67","author":"O'Kane","year":"2010","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2016.08.011_bib0475","doi-asserted-by":"publisher","first-page":"e95219","DOI":"10.1371\/journal.pone.0095219","article-title":"Activation of the PI3 K\/mTOR\/AKT pathway and survival in solid tumors: systematic review and meta-analysis","volume":"9","author":"Ocana","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.critrevonc.2016.08.011_bib0480","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1097\/JTO.0b013e3181839693","article-title":"Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma","volume":"3","author":"Okamoto","year":"2008","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2016.08.011_bib0485","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ejcts.2007.09.045","article-title":"PTEN expression is a strong predictor of survival in mesothelioma patients","volume":"33","author":"Opitz","year":"2008","journal-title":"Eur. J. Cardiothorac. Surg."},{"issue":"2","key":"10.1016\/j.critrevonc.2016.08.011_bib0490","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/JTO.0000000000000360","article-title":"SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM)","volume":"10","author":"Ou","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"15 Suppl","key":"10.1016\/j.critrevonc.2016.08.011_bib0495","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.1158\/1538-7445.AM2015-4236","article-title":"Abstract 4236: FAK inhibitor VS-6063 (defactinib) targets mesothelioma cancer stem cells, which are enriched by standard of care chemotherapy","volume":"75","author":"Pachter","year":"2015","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2016.08.011_bib0500","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/JTO.0b013e3181c5e366","article-title":"Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials","volume":"5","author":"Paik","year":"2010","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2016.08.011_bib0505","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/gcc.22068","article-title":"RNA sequencing identifies fusion of the EWSR1 and YY1 genes in mesothelioma with t(14;22)(q32;q12)","volume":"52","author":"Panagopoulos","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.critrevonc.2016.08.011_bib0510","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7582","article-title":"PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis","author":"Passiglia","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.critrevonc.2016.08.011_bib0515","doi-asserted-by":"publisher","first-page":"251","DOI":"10.4143\/crt.2013.45.4.251","article-title":"Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges","volume":"45","author":"Phillips","year":"2013","journal-title":"Cancer Res. Treat."},{"issue":"19","key":"10.1016\/j.critrevonc.2016.08.011_bib0520","first-page":"5476","article-title":"Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy","volume":"62","author":"Pietras","year":"2002","journal-title":"Cancer Res."},{"issue":"44","key":"10.1016\/j.critrevonc.2016.08.011_bib0525","doi-asserted-by":"publisher","first-page":"5960","DOI":"10.1038\/sj.onc.1209587","article-title":"Re-expression of the tumor suppressor NF2\/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK","volume":"25","author":"Poulikakos","year":"2006","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.critrevonc.2016.08.011_bib0530","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/JTO.0b013e318191520c","article-title":"Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma","volume":"4","author":"Ramalingam","year":"2009","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.08.011_bib0535","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ctrv.2014.10.007","article-title":"Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies","volume":"41","author":"Remon","year":"2015","journal-title":"Cancer Treat. Rev."},{"issue":"5","key":"10.1016\/j.critrevonc.2016.08.011_bib0540","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1093\/annonc\/mdl017","article-title":"Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors","volume":"17","author":"Richly","year":"2006","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.08.011_bib0545","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s10585-015-9755-9","article-title":"Aldehyde dehydrogenase as a marker and functional mediator of metastasis in solid tumors","volume":"33","author":"Rodriguez-Torres","year":"2016","journal-title":"Clin. Exp. Metastasis"},{"issue":"8","key":"10.1016\/j.critrevonc.2016.08.011_bib0550","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1517\/13543784.2013.812630","article-title":"BIBF 1120\/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer","volume":"22","author":"Rolfo","year":"2013","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"2","key":"10.1016\/j.critrevonc.2016.08.011_bib0555","first-page":"F115","article-title":"The p16INK4a\/CDKN2A tumor suppressor and its relatives","volume":"1378","author":"Ruas","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"issue":"19","key":"10.1016\/j.critrevonc.2016.08.011_bib0560","doi-asserted-by":"publisher","first-page":"5942","DOI":"10.1158\/1078-0432.CCR-07-0536","article-title":"Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma","volume":"13","author":"Sartore-Bianchi","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2016.08.011_bib0565","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients","volume":"18","author":"Servais","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"237","key":"10.1016\/j.critrevonc.2016.08.011_bib0570","doi-asserted-by":"publisher","first-page":"237ra268","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2016.08.011_bib0575","first-page":"3000","article-title":"Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors","volume":"30","author":"Soria","year":"2012","journal-title":"ASCO Meet. Abstr."},{"issue":"8","key":"10.1016\/j.critrevonc.2016.08.011_bib0580","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1093\/annonc\/mdv101","article-title":"Searching for targets for the systemic therapy of mesothelioma","volume":"26","author":"Stahel","year":"2015","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2016.08.011_bib0585","first-page":"181","article-title":"Activation of the PI3K-AKT pathway in human malignant mesothelioma cells","volume":"2","author":"Suzuki","year":"2009","journal-title":"Mol. Med. Rep."},{"issue":"23","key":"10.1016\/j.critrevonc.2016.08.011_bib0590","doi-asserted-by":"publisher","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-06-1101","article-title":"In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion","volume":"12","author":"Szlosarek","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2016.08.011_bib0595","first-page":"7507","article-title":"Randomized trial of arginine deprivation with pegylated arginine deiminase in patients with malignant pleural mesothelioma","volume":"32","author":"Szlosarek","year":"2014","journal-title":"ASCO Meet. Abstr."},{"issue":"10","key":"10.1016\/j.critrevonc.2016.08.011_bib0600","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.critrevonc.2016.08.011_bib0605","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.molcel.2012.03.027","article-title":"TGF-\u03b2-dependent active demethylation and expression of the p15ink4b tumor suppressor are impaired by the ZNF217\/CoREST complex","volume":"46","author":"Thillainadesan","year":"2012","journal-title":"Mol. Cell"},{"issue":"7","key":"10.1016\/j.critrevonc.2016.08.011_bib0610","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1158\/1535-7163.MCT-07-0052","article-title":"Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion","volume":"6","author":"Tsao","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2016.08.011_bib0615","first-page":"7527","article-title":"A phase I study of cediranib (NSC #732208) in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma (SWOG S0905)","volume":"31","author":"Tsao","year":"2013","journal-title":"ASCO Meet. Abstr."},{"issue":"7","key":"10.1016\/j.critrevonc.2016.08.011_bib0620","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2174\/092986708783885273","article-title":"Malignant mesothelioma resistance to apoptosis: recent discoveries and their implication for effective therapeutic strategies","volume":"15","author":"Villanova","year":"2008","journal-title":"Curr. Med. Chem."},{"issue":"2","key":"10.1016\/j.critrevonc.2016.08.011_bib0625","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/ijc.20372","article-title":"Histone deacetylase inhibitors: understanding a new wave of anticancer agents","volume":"112","author":"Villar-Garea","year":"2004","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2016.08.011_bib0630","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1053\/j.seminoncol.2005.02.010","article-title":"New agents in the management of advanced mesothelioma","volume":"32","author":"Vogelzang","year":"2005","journal-title":"Semin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2016.08.011_bib0635","first-page":"3020","article-title":"A first-in-human phase I study to evaluate GDC-0980, an oral PI3 K\/mTOR inhibitor, administered QD in patients with advanced solid tumors","volume":"29","author":"Wagner","year":"2011","journal-title":"ASCO Meet. Abstr."},{"issue":"3","key":"10.1016\/j.critrevonc.2016.08.011_bib0640","first-page":"511","article-title":"Codeletion of p15 and p16 in primary malignant mesothelioma","volume":"11","author":"Xio","year":"1995","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.critrevonc.2016.08.011_bib0645","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/jnci\/92.8.636","article-title":"Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells","volume":"92","author":"Yang","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"issue":"4","key":"10.1016\/j.critrevonc.2016.08.011_bib0650","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/JTO.0b013e3181d2f008","article-title":"Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma","volume":"5","author":"Yasumitsu","year":"2010","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2016.08.011_bib0655","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/ajim.22430","article-title":"Significant relationship between the extent of pleural plaques and pulmonary asbestos body concentration in lung cancer patients with occupational asbestos exposure","volume":"58","author":"Yusa","year":"2015","journal-title":"Am. J. Ind. Med."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2016.08.011_bib0660","first-page":"7500","article-title":"Bevacizumab 15mg\/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in malignant pleural mesothelioma (MPM): results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial","volume":"33","author":"Zalcman","year":"2015","journal-title":"ASCO Meet. Abstr."},{"issue":"10026","key":"10.1016\/j.critrevonc.2016.08.011_bib0665","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.critrevonc.2016.08.011_bib0670","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1038\/bjc.2014.220","article-title":"Multipoint targeting of the PI3K\/mTOR pathway in mesothelioma","volume":"110","author":"Zhou","year":"2014","journal-title":"Br. J. Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842816301913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842816301913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T03:52:47Z","timestamp":1568346767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842816301913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":134,"alternative-id":["S1040842816301913"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2016.08.011","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2016.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}